🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

After-Hours Movers: Amazon Sinks on Lower Guidance, Pinterest Up on Beat

Published 28/10/2022, 08:54 am
© Reuters.
INTC
-
VRTX
-
GILD
-
AAPL
-
AMZN
-
EW
-
LHX
-
DXCM
-
TMUS
-
DECK
-
PINS
-

After-Hours Stock Movers:

Amazon.com (NASDAQ:AMZN14% LOWER; reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $127.1 billion versus the consensus estimate of $127.76 billion. Amazon sees Q4 2022 revenue of $140 billion-148 billion, versus the consensus of $155.1 billion.

Edwards Lifesciences (NYSE:EW11% LOWER; reported Q3 EPS of $0.61, $0.01 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.33 billion. Edwards Lifesciences sees FY2022 EPS of $2.40-$2.50, versus the consensus of $2.52.

Pinterest (NYSE:PINS) 10% HIGHER; reported Q3 EPS of $0.11, $0.05 better than the analyst estimate of $0.06. Revenue for the quarter came in at $685 million versus the consensus estimate of $665.54 million.

L3Harris Technologies (NYSE:LHX8% LOWER; reported Q3 EPS of $3.26, $0.15 worse than the analyst estimate of $3.41. Revenue for the quarter came in at $4.25 billion versus the consensus estimate of $4.41 billion. L3Harris Technologies sees FY2022 EPS of $12.75-$13.00, versus the consensus of $13.48. L3Harris Technologies sees FY2022 revenue of $16.8 million, versus the consensus of $17.39 million.

DexCom (NASDAQ:DXCM) 7% HIGHER; reported Q3 EPS of $0.28, $0.04 better than the analyst estimate of $0.24. Revenue for the quarter came in at $769.6 million versus the consensus estimate of $751.74 million. DexCom sees Q4 2022 revenue of $2.88 billion-2.91 billion, versus the consensus of $2.89 billion.

Deckers Brands (NYSE:DECK) 6% LOWER; reported Q2 EPS of $3.80, $0.17 better than the analyst estimate of $3.63. Revenue for the quarter came in at $876 million versus the consensus estimate of $804.64 million. Deckers Brands sees FY2023 EPS of $17.50-$18.35, versus the consensus of $18.12.

Vertex Pharma (NASDAQ:VRTX) 5% HIGHER; reported Q3 EPS of $4.01, $0.39 better than the analyst estimate of $3.62. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.22 billion. Vertex Pharma sees FY2022 revenue of $8.8 billion-8.9 billion, versus the prior of $8.6 billion-$8.8 billion and the consensus of $8.77 billion.

Gilead Sciences (NASDAQ:GILD4% HIGHER; reported Q3 EPS of $1.90, $0.38 better than the analyst estimate of $1.52. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.13 billion.

Intel (NASDAQ:INTC) 4% HIGHER; reported Q3 EPS of $0.59, $0.25 better than the analyst estimate of $0.34. Revenue for the quarter came in at $15.3 billion versus the consensus estimate of $15.43 billion. Intel sees Q4 2022 EPS of $0.20, versus the consensus of $0.60. Intel sees Q4 2022 revenue of $14 billion-15 billion, versus the consensus of $16.3 billion

T-Mobile (NASDAQ:TMUS) 3% HIGHER; reported Q3 EPS of $0.40, $0.01 better than the analyst estimate of $0.39. Revenue for the quarter came in at $19.48 billion versus the consensus estimate of $20.02 billion.

Apple Inc (NASDAQ:AAPL1% LOWER; reported Q4 EPS of $1.29, $0.03 better than the analyst estimate of $1.26. Revenue for the quarter came in at $90.1 billion versus the consensus estimate of $88.76 billion.

 
 
 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.